WO2010001485A1 - Adsorbent for oral administration - Google Patents
Adsorbent for oral administration Download PDFInfo
- Publication number
- WO2010001485A1 WO2010001485A1 PCT/JP2008/062219 JP2008062219W WO2010001485A1 WO 2010001485 A1 WO2010001485 A1 WO 2010001485A1 JP 2008062219 W JP2008062219 W JP 2008062219W WO 2010001485 A1 WO2010001485 A1 WO 2010001485A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- activated carbon
- spherical activated
- adsorbent
- oral administration
- protrusions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/44—Elemental carbon, e.g. charcoal, carbon black
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B32/00—Carbon; Compounds thereof
- C01B32/30—Active carbon
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B32/00—Carbon; Compounds thereof
- C01B32/30—Active carbon
- C01B32/312—Preparation
- C01B32/336—Preparation characterised by gaseous activating agents
Definitions
- the present invention relates to an adsorbent for oral administration.
- Hemodialysis is the most popular treatment method for removing toxic substances from the body.
- this treatment requires not only a special device but also a long time for the treatment, which causes physical and mental pain to the patient.
- adsorbents that adsorb harmful toxic substances in the intestine by oral administration have been developed for the purpose of suppressing the progression of renal diseases.
- This adsorbent is made of spherical activated carbon having specific physical properties, and several patent applications have been made and are commercially available.
- Japanese Patent No. 3585043 uses a spherical phenol resin as a raw material, and has an average particle diameter of 350 ⁇ m or less, a specific surface area of 800 to 2000 m 2 / g, a pore volume of 0.2 to 1.0 mL / g, and a diameter of 1.0 nm or less.
- a medical adsorbent having physical properties such that the pores are 55% or more of the total pore volume and the pore volume of 20 to 1000 nm in diameter is 0.04 mL / g or less is disclosed.
- Japanese Patent Application Laid-Open No. 2006-15334 has physical properties of an average particle diameter of 100 to 800 ⁇ m, a specific surface area of 800 to 3000 m 2 / g, and a pore volume of 0.02 to 10 ⁇ m in diameter of 0.10 to 0.60 mL / g. Medical adsorbents are disclosed.
- adsorbents described in any of the patent documents have high adsorptivity for harmful toxic substances such as indole.
- these adsorbents are relatively unsatisfactory in terms of the selective adsorptivity of harmful toxic substances because they have a relatively high adsorptivity for necessary substances such as tryptophan and lysine.
- the present invention relates to an adsorbent for oral administration that has a high adsorptivity to harmful toxic substances such as indole and a low adsorptivity to necessary substances such as tryptophan and lysine, and has an excellent selective adsorptivity for harmful toxic substances.
- the purpose is to provide.
- a spherical activated carbon having a large number of protrusions on the surface, a total pore volume of 0.2 to 0.5 cc / g, and a volume ratio of pores having a diameter of 1 nm or less of 30 to 45% is obtained.
- An adsorbent for oral administration is provided.
- FIG. 1 is a SEM photograph showing the surface state of the spherical activated carbon of Example 1.
- FIG. 2 is a SEM photograph showing the surface state of the spherical activated carbon of Example 2.
- FIG. 3 is a SEM photograph showing the surface state of the spherical activated carbon of Example 3.
- 4 is a SEM photograph showing the surface state of the spherical activated carbon of Example 4.
- FIG. 5 is a SEM photograph showing the surface state of the spherical activated carbon of Example 5.
- FIG. 6 is a SEM photograph showing the surface state of the spherical activated carbon of Comparative Example 1.
- FIG. 7 is an SEM photograph showing the surface state of the spherical activated carbon of Comparative Example 2.
- FIG. 8 is a SEM photograph showing the surface state of the spherical activated carbon of Comparative Example 3.
- the adsorbent for oral administration according to the embodiment has a large number of protrusions formed on the surface, the total pore volume is 0.2 to 0.5 cc / g, and the volume ratio of pores having a diameter of 1 nm or less is 30 to 45. % Spherical activated carbon.
- a large number of protrusions formed on the surface of the spherical activated carbon have a shape having a curve on at least a part of the outer edge on the surface (for example, SEM photograph) on which the spherical activated carbon is projected.
- a shape having a curve on at least a part of the outer edge means a shape in which all the outer edges are curved, and a shape in which the outer edge is a straight line and a curve connected from one end of the straight line to the other end.
- Examples of the shape in which the outer edges are all curved include a circle, an ellipse, a flat ellipse, and a shape that is bound to a part of the outer edge of the ellipse.
- Examples of the shape composed of a straight line and a curve connecting from one end of the straight line to the other end include a shape in which a part of the outer edge of the circle forms a straight line, a shape in which a part of the outer edge of the ellipse forms a straight line, and the like.
- the protrusions of these shapes may be formed individually on the surface of the spherical activated carbon or may be formed together.
- the projection having such a shape preferably has a diameter of 0.1 to 1.2 ⁇ m.
- the “projection diameter” is the maximum length of the length that crosses the center from two points on the outer edge by observing a protrusion having a curved shape on at least a part of the outer edge on the surface on which the spherical activated carbon is projected. Means.
- the diameter is a diameter.
- the number of protrusions present per 1 ⁇ m 2 on the spherical activated carbon surface can be calculated by the following method. That is, SEM photographs at a predetermined magnification are taken at a plurality of locations on the surface of the spherical activated carbon. The number of protrusions projected on each SEM photograph is measured.
- the number of protrusions per 1 ⁇ m 2 is calculated in each SEM photograph.
- An average value of the number of protrusions per 1 ⁇ m 2 is obtained from the calculated number of protrusions per 1 ⁇ m 2 and the number of SEM photographs.
- the number of protrusions in which the missing protrusion is half or more of the normal size is measured. Exclude from measurement.
- the number of protrusions is obtained as an average value as described above, the number of protrusions per 1 ⁇ m 2 may not have an integer but may have a decimal point.
- the height of the protrusion formed on the surface of the spherical activated carbon is not particularly limited, but is preferably 0.04 to 0.2 ⁇ m.
- Adsorbability of harmful toxic substances by spherical activated carbon can be improved by defining the total pore volume to 0.2 to 0.5 cc / g.
- the volume ratio of pores having a diameter of 1 nm or less means the ratio of the pores to the total pore volume.
- Spherical activated carbon with a volume ratio of pores with a diameter of 1 nm or less of 30-45% improves the adsorptivity of harmful toxic substances and selectively adsorbs harmful toxic substances in order to suppress the adsorptivity of necessary substances in the body. Can be improved. If the volume ratio of pores having a diameter of 1 nm or less is less than 30%, the adsorptivity of harmful toxic substances may be reduced.
- volume ratio of pores having a diameter of 1 nm or less exceeds 45%, the adsorptivity of harmful toxic substances increases, but the adsorptivity of necessary substances in living bodies also increases, and the selective adsorptivity of harmful toxic substances. May decrease.
- a more preferable volume ratio of pores having a diameter of 1 nm or less is 34 to 41%.
- the spherical activated carbon preferably further has the following physical properties.
- the specific surface area determined by the BET method is 600 m 2 / g to 1000 m 2 / g.
- the adsorptivity of harmful toxic substances by the spherical activated carbon can be further improved by defining the specific surface area within the above range.
- the average particle size is 250 ⁇ m or more.
- the upper limit of the average particle diameter is preferably 800 ⁇ m.
- the particle strength is 10,000 g / mm 2 or more.
- Spherical activated carbon having a particle strength of 10,000 g / mm 2 or more can prevent fine particles in the intestine during oral administration and prevent adhesion to the intestinal wall.
- the upper limit of the particle strength is preferably 18000 g / mm 2 .
- a cured spherical phenol resin is produced by a condensation reaction of phenols and aldehydes in the presence of an emulsion stabilizer.
- Phenols include, for example, phenol, cresol, xylenol; phenols having 1 to 4 alkyl groups having 1 to 10 carbon atoms as substituents, such as ethylphenol, propylphenol, and butylphenol; phenylphenol, resorcinol, catechol, and pyrogallol. Can be used.
- aldehydes for example, formaldehyde, acetaldehyde, or benzenes having a formyl group can be used.
- emulsion stabilizer for example, gum arabic (Senegal species) can be used.
- the raw materials and the emulsion stabilizer can be used alone or in combination of two or more.
- the obtained cured spherical phenol is baked by a baking apparatus such as a rotary kiln. Subsequently, water is added, and the activated carbon is heated to about 1000 ° C. to activate water vapor to produce spherical activated carbon.
- the adsorbent for oral administration according to the embodiment is composed of spherical activated carbon having the above physical properties alone or a mixture of many kinds of spherical activated carbon having the above physical properties.
- Examples of the dosage form of the adsorbent for oral administration according to the embodiment include powders, fine granules, granules, tablets, capsules, suspensions, and jelly agents.
- the jelly agent containing the spherical activated carbon or the spherical activated carbon Tablets having a rapidly disintegrating function are preferred.
- a suspension containing the spherical activated carbon which is easy to process and ensures the uniformity of components, is preferable.
- a flavoring agent for example, a flavoring agent, a coloring agent, a flavoring agent, a preservative, a gelling agent, an emulsifier, and a pH adjuster are blended in the spherical activated carbon.
- a disintegrating agent, a lubricant, a binder, an excipient, a fluidizing agent, a coloring agent, a flavoring agent, a sweetening agent and a stabilizing agent are blended in the spherical activated carbon.
- the suspending agent a coloring agent, a flavoring agent, an antiseptic, a gelling agent, an emulsifier, a pH adjusting agent, a buffering agent, a suspending agent, a dispersing agent, an antifoaming agent and a thickening agent are blended in the spherical activated carbon.
- the adsorbent for oral administration has a large number of protrusions formed on the surface, a total pore volume of 0.2 to 0.5 cc / g, and a volume ratio of pores having a diameter of 1 nm or less. Because it contains spherical activated carbon that is 30-45%, it has a high adsorptivity to harmful toxic substances such as indole due to the interaction of many protrusions and the volume ratio of pores. Excellent selective adsorption with low adsorption of necessary substances.
- the diameter of the protrusion having a curved shape on at least a part of the outer edge be 0.1 to 1.2 ⁇ m
- further excellent selective adsorption of harmful toxic substances can be achieved.
- the adsorbent for oral administration can be obtained.
- the contact area with the intestinal inner wall can be reduced as compared with the spherical activated carbon having a smooth surface, so that adhesion to the intestinal inner wall can be suppressed. As a result, it becomes possible to prevent constipation associated with adhesion to the intestinal inner wall.
- Example 1 In a reaction vessel equipped with a thermometer, a stirrer and a reflux condenser, 500 parts by mass of phenol, 260 parts by mass of solid paraformaldehyde containing 8% by mass of water, 750 parts by mass of water, 5 parts by mass of dodecylbenzenesulfonic acid, and After charging 0.2 parts by mass of gum arabic (Senegal seed), the contents were heated and reacted with stirring. After the reaction, the inside of the reaction vessel was cooled to room temperature and washed after filtration to obtain a cured spherical phenol resin.
- 500 parts by mass of phenol 500 parts by mass of phenol, 260 parts by mass of solid paraformaldehyde containing 8% by mass of water, 750 parts by mass of water, 5 parts by mass of dodecylbenzenesulfonic acid, and After charging 0.2 parts by mass of gum arabic (Senegal seed), the contents were heated and reacted with stirring. After the reaction
- Example 2 300 parts by mass of the cured spherical phenol resin obtained by the same method as in Example 1 was charged into a rotary kiln, and then heated to 900 ° C. and baked for 1 hour. Subsequent to firing, the mixture was heated to 1000 ° C. while adding water, subjected to steam activation for 0.5 hours, and then cooled to room temperature to produce spherical activated carbon.
- Example 3 300 parts by mass of the cured spherical phenol resin obtained by the same method as in Example 1 was charged into a rotary kiln, and then heated to 900 ° C. and baked for 1 hour. Subsequent to the firing, the mixture was cooled to 800 ° C., subjected to steam activation for 3 hours while adding water, and then cooled to room temperature to produce spherical activated carbon.
- Example 4 300 parts by mass of the cured spherical phenol resin obtained by the same method as in Example 1 was charged into a rotary kiln, and then heated to 900 ° C. and baked for 1 hour. Following the firing, the mixture was cooled to 800 ° C., and steam activation was carried out for 4 hours while adding water. After heating again to 1000 degreeC and baking for 0.5 hour, it cooled to room temperature and manufactured spherical activated carbon.
- Example 5 300 parts by mass of the cured spherical phenol resin obtained by the same method as in Example 1 was charged into a rotary kiln, and then heated to 900 ° C. and baked for 1 hour. Following the firing, the mixture was cooled to 800 ° C., and steam activation was performed for 5 hours while adding water, and then cooled to room temperature to produce spherical activated carbon.
- Comparative Example 1 300 parts by mass of the cured spherical phenol resin obtained by the same method as in Example 1 was charged into a rotary kiln, and then heated to 900 ° C. and baked for 1 hour. Subsequent to firing, the mixture was cooled to 800 ° C., subjected to steam activation for 2 hours while adding water, and then cooled to room temperature to produce spherical activated carbon.
- the number of protrusions projected on the three SEM photographs was measured. By dividing the measured number of protrusions by the area obtained from the magnification of the SEM photograph, the number of protrusions projected on each SEM photograph per 1 ⁇ m 2 was calculated. The average number of protrusions per 1 ⁇ m 2 on the surface of the spherical activated carbon was determined by adding the number of protrusions per 1 ⁇ m 2 calculated from the three SEM photographs and dividing this added number by 3. The results are shown in Table 1 below. In addition, when a protrusion existing in the field of view of the SEM photograph is missing at the edge of the field of view, the number of protrusions in which the missing protrusion is half or more of the normal size is measured. Excluded from measurement. The number of protrusions per 1 ⁇ m 2 in Table 1 below is a value obtained by rounding off the first decimal place.
- the specific surface area and pore volume were measured by the multipoint BET method at a relative pressure (P / P 0 ) of 0.02 to 0.2.
- the volume ratio of pores having a diameter of 1 nm or less was determined by measuring the pore distribution by the MP method and calculating the ratio of the total pore volume of pores having a diameter of 1 nm or less to the total pore volume.
- Average particle size of spherical activated carbon The particle size distribution of spherical activated carbon was measured by a light scattering method using a particle size distribution measuring device (manufactured by Nikkiso Co., Ltd .; Microtrac particle size distribution measuring device 9320HRA (x-100)). From this particle size distribution, when the cumulative curve was determined by setting the volume of the entire particle to 100%, the particle size at which the curve reached 50% was determined as the average particle size. That is, the cumulative average diameter (center diameter: Median diameter) was taken as the average particle diameter.
- Particle strength of spherical activated carbon The spherical activated carbon was sieved to a particle size of 355 ⁇ m or more and less than 425 ⁇ m. One particle was weighted, the load when the particle was crushed was measured, and the particle strength was calculated from the following equation.
- a particle hardness measuring device Okada Seiko Co., Ltd .: Grano
- ⁇ Indole adsorption test> Each spherical activated carbon was pretreated by drying at 105 ° C. for 2 hours, and then accurately weighed 0.01 g and put into a conical flask with a stopper. An indole stock solution having a concentration of 50 ppm prepared with a phosphate buffer solution at pH 7.4 was accurately collected using a 50 mL whole pipette and transferred to the Erlenmeyer flask. Subsequently, the Erlenmeyer flask was placed in a 40 ° C. water bath and shaken for 3 hours.
- the liquid was collected from the Erlenmeyer flask and filtered through a chromatodisc having a pore size of 0.45 ⁇ m.
- the absorbance of light with a wavelength of 265 nm was measured for the filtrate, and the amount of adsorption was calculated. That is, the absorbance at 0% indole stock solution (pH 7.4 phosphate buffer), 25%, 50%, 75% and 100% was measured to prepare a calibration curve showing the relationship between the indole concentration and the absorbance. The actually measured absorbance was collated with this calibration curve to calculate the indole concentration of the filtrate.
- the indole adsorption amount of each spherical activated carbon was determined by subtracting the initial indole concentration from the calculated indole concentration.
- ⁇ Tryptophan adsorption test> The tryptophan adsorption amount of each spherical activated carbon was determined according to the indole adsorption test except that the tryptophan stock solution was 100 ppm, the temperature at shaking was 37 ° C., and the light wavelength at the time of absorbance measurement was 280 nm.
- the liquid was collected from the Erlenmeyer flask and filtered through a chromatodisc having a pore size of 0.45 ⁇ m.
- the filtrate was subjected to amino acid analysis using an amino acid analyzer (JEOL Ltd .; JLC-500 / V2) and a high resolution column.
- the amount of lysine adsorbed on each spherical activated carbon was determined by subtracting the initial lysine concentration from the lysine concentration measured in this analysis.
- the spherical activated carbons of Examples 1 to 5 are commercially available with no protrusions on the surface and smooth, and the volume ratio of pores having a diameter of 1 nm or less exceeds the upper limit of 45% of the present invention.
- the indole adsorptivity is slightly inferior to the spherical activated carbons of Comparative Examples 2 and 3, which are products, the adsorbability of tryptophan and lysine, which are vital substances, is low, and the indole selective adsorptivity is excellent. I understand that.
- the spherical activated carbon of Comparative Example 1 has a large number of protrusions on the surface, the volume ratio of pores having a diameter of 1 nm or less is less than 30% (29.6%) of the lower limit of the present invention. It can be seen that the adsorptivity of is extremely lower than the spherical activated carbons of Examples 1 to 5.
- the adsorptivity of harmful toxic substances such as indole is high, the adsorptivity of necessary substances such as tryptophan and lysine is low, the selective adsorptivity of harmful toxic substances is excellent, and the kidney function Therefore, it is possible to provide an adsorbent for oral administration that is useful as a therapeutic agent for patients with reduced blood pressure.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
本発明は、経口投与用吸着剤に関する。 The present invention relates to an adsorbent for oral administration.
腎臓機能が低下した患者らは、血液中の窒素性物質および他の老廃物のような有害な毒性物質を尿から十分に排泄できない。このため、毒性物質が体内に蓄積し、意識障害のような尿毒症症状を引き起こす可能性がある。したがって、毒性物質の除去は腎疾患の進行を抑制する上で、極めて重要である。 Patients with impaired kidney function cannot excrete toxic toxic substances such as nitrogenous substances in the blood and other waste products from the urine. For this reason, toxic substances can accumulate in the body and cause uremia symptoms such as impaired consciousness. Therefore, removal of toxic substances is extremely important in suppressing the progression of renal diseases.
血液透析は、毒性物質を体内より除去する方法で、最も普及している治療方法である。しかしながら、この治療には特殊な装置を必要とするだけでなく、治療に要する時間が長いために患者に肉体的、精神的な苦痛を生じさせる。 Hemodialysis is the most popular treatment method for removing toxic substances from the body. However, this treatment requires not only a special device but also a long time for the treatment, which causes physical and mental pain to the patient.
一方、腎疾患の進行抑制を目的として経口投与により腸内の有害な毒性物質を吸着する吸着剤が開発されている。この吸着剤は、特定の物性を有する球状活性炭からなるもので、いくつかの特許出願がなされ、かつ市販されている。 On the other hand, adsorbents that adsorb harmful toxic substances in the intestine by oral administration have been developed for the purpose of suppressing the progression of renal diseases. This adsorbent is made of spherical activated carbon having specific physical properties, and several patent applications have been made and are commercially available.
例えば、特許第3585043号には球状フェノール樹脂を原料物質とし、平均粒子径350μm以下、比表面積800~2000m2/g、細孔容積0.2~1.0mL/g、直径1.0nm以下の細孔が全細孔容積の55%以上、直径20~1000nmの細孔容積が0.04mL/g以下の物性を有する医療用吸着剤が開示されている。 For example, Japanese Patent No. 3585043 uses a spherical phenol resin as a raw material, and has an average particle diameter of 350 μm or less, a specific surface area of 800 to 2000 m 2 / g, a pore volume of 0.2 to 1.0 mL / g, and a diameter of 1.0 nm or less. A medical adsorbent having physical properties such that the pores are 55% or more of the total pore volume and the pore volume of 20 to 1000 nm in diameter is 0.04 mL / g or less is disclosed.
特開2006-15334号公報には、平均粒子径100~800μm、比表面積800~3000m2/g、直径0.02~10μmの細孔容積が0.10~0.60mL/gの物性を有する医療用吸着剤が開示されている。 Japanese Patent Application Laid-Open No. 2006-15334 has physical properties of an average particle diameter of 100 to 800 μm, a specific surface area of 800 to 3000 m 2 / g, and a pore volume of 0.02 to 10 μm in diameter of 0.10 to 0.60 mL / g. Medical adsorbents are disclosed.
いずれの特許文献に記載された吸着剤は、インドールのような有害な毒性物質の吸着性が高い。しかしながら、これらの吸着剤はトリプトファン、リジンのような生体の必要物質の吸着性も比較的高いため、有害な毒性物質の選択吸着性の点で十分に満足するものではない。 The adsorbents described in any of the patent documents have high adsorptivity for harmful toxic substances such as indole. However, these adsorbents are relatively unsatisfactory in terms of the selective adsorptivity of harmful toxic substances because they have a relatively high adsorptivity for necessary substances such as tryptophan and lysine.
本発明は、インドールのような有害な毒性物質の吸着性が高く、トリプトファン、リジンのような生体の必要物質の吸着性が低い、有害な毒性物質の選択吸着性に優れた経口投与用吸着剤を提供することを目的とする。 The present invention relates to an adsorbent for oral administration that has a high adsorptivity to harmful toxic substances such as indole and a low adsorptivity to necessary substances such as tryptophan and lysine, and has an excellent selective adsorptivity for harmful toxic substances. The purpose is to provide.
本発明によると、表面に多数の突起が形成され、全細孔容積が0.2~0.5cc/gで、かつ直径1nm以下の細孔の容積率が30~45%である球状活性炭を含む経口投与用吸着剤が提供される。 According to the present invention, a spherical activated carbon having a large number of protrusions on the surface, a total pore volume of 0.2 to 0.5 cc / g, and a volume ratio of pores having a diameter of 1 nm or less of 30 to 45% is obtained. An adsorbent for oral administration is provided.
以下、本発明の実施形態に係る経口投与用吸着剤を詳細に説明する。 Hereinafter, the adsorbent for oral administration according to the embodiment of the present invention will be described in detail.
実施形態に係る経口投与用吸着剤は、表面に多数の突起が形成され、全細孔容積が0.2~0.5cc/gで、かつ直径1nm以下の細孔の容積率が30~45%である球状活性炭を含む。 The adsorbent for oral administration according to the embodiment has a large number of protrusions formed on the surface, the total pore volume is 0.2 to 0.5 cc / g, and the volume ratio of pores having a diameter of 1 nm or less is 30 to 45. % Spherical activated carbon.
球状活性炭の表面に形成した多数の突起は、球状活性炭を投影した面(例えばSEM写真)において、外縁の少なくとも一部に曲線を持つ形状をなす。ここで、“外縁の少なくとも一部に曲線を持つ形状”とは、全ての外縁が曲線である形状、外縁が直線とこの直線の一端から他端に繋がる曲線とからなる形状を意味する。外縁が全て曲線である形状は、例えば円、楕円または扁平楕円、楕円の一部の外縁に括れもつ形状等が挙げられる。外縁が直線とこの直線の一端から他端に繋がる曲線とからなる形状は、例えば円の一部の外縁が直線をなす形状、楕円の一部の外縁が直線をなす形状等を挙げることができる。これらの形状の突起は、球状活性炭表面にそれぞれ単独で形成されても、混在して形成されてもよい。 A large number of protrusions formed on the surface of the spherical activated carbon have a shape having a curve on at least a part of the outer edge on the surface (for example, SEM photograph) on which the spherical activated carbon is projected. Here, “a shape having a curve on at least a part of the outer edge” means a shape in which all the outer edges are curved, and a shape in which the outer edge is a straight line and a curve connected from one end of the straight line to the other end. Examples of the shape in which the outer edges are all curved include a circle, an ellipse, a flat ellipse, and a shape that is bound to a part of the outer edge of the ellipse. Examples of the shape composed of a straight line and a curve connecting from one end of the straight line to the other end include a shape in which a part of the outer edge of the circle forms a straight line, a shape in which a part of the outer edge of the ellipse forms a straight line, and the like. . The protrusions of these shapes may be formed individually on the surface of the spherical activated carbon or may be formed together.
このような形状の突起は、0.1~1.2μmの径を有することが好ましい。ここで、“突起の径”とは球状活性炭を投影した面において、外縁の少なくとも一部に曲線を持つ形状の突起を観察し、外縁の2点から中心を横切る長さのうちの最大長さを意味する。例えば、円形の突起の場合にはその径は直径になる。 The projection having such a shape preferably has a diameter of 0.1 to 1.2 μm. Here, the “projection diameter” is the maximum length of the length that crosses the center from two points on the outer edge by observing a protrusion having a curved shape on at least a part of the outer edge on the surface on which the spherical activated carbon is projected. Means. For example, in the case of a circular protrusion, the diameter is a diameter.
多数の突起は、球状活性炭表面に1μm2あたり1~20個、より好ましくは1~15個、最も好ましくは1~10個形成されることが望ましい。ここで、球状活性炭表面に1μm2あたり存在する突起の個数は次の方法により算出することができる。すなわち、球状活性炭表面の複数個所で所定の倍率のSEM写真を撮影する。各SEM写真に映し出された突起の個数を計測する。計測した突起個数を撮影時の倍率から求めたSEM写真の面積で除すことにより、各SEM写真において1μm2当たりの突起の個数を計算する。これらの計算した1μm2当たりの突起個数とSEM写真の数とから1μm2当たりの突起個数の平均値を求める。なお、SEM写真の視野に存在する突起がその視野の縁部で欠けている場合には、欠けた突起が正規の大きさの半分以上である突起は1個として計測し、それ未満の突起は計測の対象から除外する。また、突起の個数は前述したように平均値として求めるため、1μm2当たりの突起個数は整数にならずに小数点を持つ場合もある。 It is desirable that a large number of protrusions be formed on the surface of the spherical activated carbon at 1 to 20, more preferably 1 to 15, most preferably 1 to 10 per 1 μm 2 . Here, the number of protrusions present per 1 μm 2 on the spherical activated carbon surface can be calculated by the following method. That is, SEM photographs at a predetermined magnification are taken at a plurality of locations on the surface of the spherical activated carbon. The number of protrusions projected on each SEM photograph is measured. By dividing the measured number of protrusions by the area of the SEM photograph obtained from the magnification at the time of photographing, the number of protrusions per 1 μm 2 is calculated in each SEM photograph. An average value of the number of protrusions per 1 μm 2 is obtained from the calculated number of protrusions per 1 μm 2 and the number of SEM photographs. In addition, when a protrusion existing in the field of view of the SEM photograph is missing at the edge of the field of view, the number of protrusions in which the missing protrusion is half or more of the normal size is measured. Exclude from measurement. Further, since the number of protrusions is obtained as an average value as described above, the number of protrusions per 1 μm 2 may not have an integer but may have a decimal point.
球状活性炭表面に形成した突起の高さは、特に限定しないが、0.04~0.2μmであることが好ましい。 The height of the protrusion formed on the surface of the spherical activated carbon is not particularly limited, but is preferably 0.04 to 0.2 μm.
球状活性炭による有害な毒性物質の吸着性は、その全細孔容積を0.2~0.5cc/gに規定することにより向上させることが可能になる。 Adsorbability of harmful toxic substances by spherical activated carbon can be improved by defining the total pore volume to 0.2 to 0.5 cc / g.
球状活性炭において、直径1nm以下の細孔の容積率はその細孔が全細孔容積に対して占める割合を意味する。直径1nm以下の細孔の容積率が30~45%である球状活性炭は、有害な毒性物質の吸着性を向上すると共に、生体の必要物質の吸着性を抑えるために有害な毒性物質の選択吸着性を向上できる。直径1nm以下の細孔の容積率を30%未満にすると、有害な毒性物質の吸着性が低下する虞がある。一方、直径1nm以下の細孔の容積率が45%を超えると、有害な毒性物質の吸着性が高くなるものの、生体の必要物質の吸着性も高くなって、有害な毒性物質の選択吸着性が低下する虞がある。より好ましい直径1nm以下の細孔の容積率は、34~41%である。 In spherical activated carbon, the volume ratio of pores having a diameter of 1 nm or less means the ratio of the pores to the total pore volume. Spherical activated carbon with a volume ratio of pores with a diameter of 1 nm or less of 30-45% improves the adsorptivity of harmful toxic substances and selectively adsorbs harmful toxic substances in order to suppress the adsorptivity of necessary substances in the body. Can be improved. If the volume ratio of pores having a diameter of 1 nm or less is less than 30%, the adsorptivity of harmful toxic substances may be reduced. On the other hand, if the volume ratio of pores having a diameter of 1 nm or less exceeds 45%, the adsorptivity of harmful toxic substances increases, but the adsorptivity of necessary substances in living bodies also increases, and the selective adsorptivity of harmful toxic substances. May decrease. A more preferable volume ratio of pores having a diameter of 1 nm or less is 34 to 41%.
球状活性炭は、次の物性をさらに有することが好ましい。 The spherical activated carbon preferably further has the following physical properties.
(1)BET法により求められる比表面積が600m2/g~1000m2/gである。球状活性炭による有害な毒性物質の吸着性は、比表面積を前記範囲に規定することによって、一層向上させることが可能になる。 (1) The specific surface area determined by the BET method is 600 m 2 / g to 1000 m 2 / g. The adsorptivity of harmful toxic substances by the spherical activated carbon can be further improved by defining the specific surface area within the above range.
(2)平均粒子径が250μm以上である。平均粒子径の上限は、800μmであることが好ましい。 (2) The average particle size is 250 μm or more. The upper limit of the average particle diameter is preferably 800 μm.
(3)粒子強度が10000g/mm2以上である。粒子強度が10000g/mm2以上の球状活性炭は、経口投与時の腸内での微粉化を抑制して腸壁面への付着を防止することが可能になる。粒子強度の上限は、18000g/mm2であることが好ましい。 (3) The particle strength is 10,000 g / mm 2 or more. Spherical activated carbon having a particle strength of 10,000 g / mm 2 or more can prevent fine particles in the intestine during oral administration and prevent adhesion to the intestinal wall. The upper limit of the particle strength is preferably 18000 g / mm 2 .
このような球状活性炭の各種物性の測定方法は、後の実施例で詳述する。 The method for measuring various physical properties of such a spherical activated carbon will be described in detail in later examples.
次に、実施形態に係る経口投与用吸着剤に含まれる球状活性炭の製造方法の一例を説明する。 Next, an example of a method for producing spherical activated carbon contained in the orally administered adsorbent according to the embodiment will be described.
まず、フェノール類とアルデヒド類とを乳化安定剤の存在下で縮合反応させることにより硬化球状フェノール樹脂を生成する。 First, a cured spherical phenol resin is produced by a condensation reaction of phenols and aldehydes in the presence of an emulsion stabilizer.
フェノール類は、例えばフェノール、クレゾール、キシレノール;エチルフェノール、プロピルフェノール、ブチルフェノールのような炭素数1~10のアルキル基を置換基として1~4個有するフェノール類;フェニルフェノール、レゾルシノール、カテコール、ピロガロールを用いることができる。 Phenols include, for example, phenol, cresol, xylenol; phenols having 1 to 4 alkyl groups having 1 to 10 carbon atoms as substituents, such as ethylphenol, propylphenol, and butylphenol; phenylphenol, resorcinol, catechol, and pyrogallol. Can be used.
アルデヒド類は、例えばホルムアルデヒド、アセトアルデヒド、またはホルミル基を有するベンゼン類を用いることができる。 As the aldehydes, for example, formaldehyde, acetaldehyde, or benzenes having a formyl group can be used.
乳化安定剤は、例えばアラビアゴム(セネガル種)を用いることができる。 As the emulsion stabilizer, for example, gum arabic (Senegal species) can be used.
前記原料および乳化安定剤は、それぞれ単独または2種以上組み合わせて用いることができる。 The raw materials and the emulsion stabilizer can be used alone or in combination of two or more.
次いで、得られた硬化球状フェノールを例えばロータリーキルンのような焼成装置で焼成する。ひきつづいて、水を添加し、1000℃前後に昇温して水蒸気賦活を行なうことにより球状活性炭を製造する。 Next, the obtained cured spherical phenol is baked by a baking apparatus such as a rotary kiln. Subsequently, water is added, and the activated carbon is heated to about 1000 ° C. to activate water vapor to produce spherical activated carbon.
実施形態に係る経口投与用吸着剤は、前記物性を有する球状活性炭を単独または前記物性を有する球状活性炭を多数種混合して構成される。 The adsorbent for oral administration according to the embodiment is composed of spherical activated carbon having the above physical properties alone or a mixture of many kinds of spherical activated carbon having the above physical properties.
実施形態に係る経口投与用吸着剤の剤形は、例えば散剤、細粒剤、顆粒剤、錠剤、カプセル剤、懸濁剤またはゼリー剤を挙げることができる。高齢者の嚥下機能が低下した患者への適用、透析患者のような水分制限が課せられた患者への適用、服用感の良さを考慮した場合、前記球状活性炭を含むゼリー剤または前記球状活性炭を含む速崩壊性機能を有する錠剤が好適である。良好な服用感のみを得る場合には、加工のし易さおよび成分の均一性の担保が容易な前記球状活性炭を含む懸濁剤が好適である。 Examples of the dosage form of the adsorbent for oral administration according to the embodiment include powders, fine granules, granules, tablets, capsules, suspensions, and jelly agents. In consideration of application to patients with swallowing function of elderly people, application to patients with water restriction such as dialysis patients, good sensation of taking, the jelly agent containing the spherical activated carbon or the spherical activated carbon Tablets having a rapidly disintegrating function are preferred. In order to obtain only a good feeling of dosing, a suspension containing the spherical activated carbon, which is easy to process and ensures the uniformity of components, is preferable.
ゼリー剤は、例えば嬌味剤、着色剤、着香剤、防腐剤、ゲル化剤、乳化剤およびpH調整剤が前記球状活性炭に配合される。速崩壊性機能を有する錠剤は、崩壊剤、滑沢剤、結合剤、賦形剤、流動化剤、着色剤、着香剤、甘味剤および安定化剤が前記球状活性炭に配合される。懸濁剤は、着色剤、着香剤、防腐剤、ゲル化剤、乳化剤、pH調整剤、緩衝剤、懸濁化剤、分散剤、消泡剤および粘稠剤が前記球状活性炭に配合される。 As the jelly agent, for example, a flavoring agent, a coloring agent, a flavoring agent, a preservative, a gelling agent, an emulsifier, and a pH adjuster are blended in the spherical activated carbon. In the tablet having a quick disintegrating function, a disintegrating agent, a lubricant, a binder, an excipient, a fluidizing agent, a coloring agent, a flavoring agent, a sweetening agent and a stabilizing agent are blended in the spherical activated carbon. As for the suspending agent, a coloring agent, a flavoring agent, an antiseptic, a gelling agent, an emulsifier, a pH adjusting agent, a buffering agent, a suspending agent, a dispersing agent, an antifoaming agent and a thickening agent are blended in the spherical activated carbon. The
以上説明した実施形態に係る経口投与用吸着剤は、表面に多数の突起が形成され、全細孔容積が0.2~0.5cc/gで、かつ直径1nm以下の細孔の容積率が30~45%である球状活性炭を含むため、多数の突起と細孔の容積率の規定による相互作用によって、インドールのような有害な毒性物質の吸着性が高く、トリプトファン、リジンのような生体の必要物質の吸着性が低い、優れた選択吸着性を示す。 The adsorbent for oral administration according to the embodiment described above has a large number of protrusions formed on the surface, a total pore volume of 0.2 to 0.5 cc / g, and a volume ratio of pores having a diameter of 1 nm or less. Because it contains spherical activated carbon that is 30-45%, it has a high adsorptivity to harmful toxic substances such as indole due to the interaction of many protrusions and the volume ratio of pores. Excellent selective adsorption with low adsorption of necessary substances.
特に、球状活性炭を投影した面において、外縁の少なくとも一部に曲線を持つ形状をなす突起の径を0.1~1.2μmにすることによって、さらに優れた有害な毒性物質の選択吸着性を有する経口投与用吸着剤を得ることができる。また、前記形状および径を持つ突起を球状活性炭表面に1μm2あたり1~20個形成させることによって、より一層優れた有害な毒性物質の選択吸着性を有する経口投与用吸着剤を得ることができる。 In particular, on the surface projected with spherical activated carbon, by making the diameter of the protrusion having a curved shape on at least a part of the outer edge be 0.1 to 1.2 μm, further excellent selective adsorption of harmful toxic substances can be achieved. The adsorbent for oral administration can be obtained. Further, by forming 1 to 20 protrusions having the shape and diameter on the surface of the spherical activated carbon per 1 μm 2, it is possible to obtain an adsorbent for oral administration having even more excellent selective adsorption of harmful toxic substances. .
また、球状活性炭は表面に多数の突起が形成されるため、表面が平滑な球状活性炭に比べて腸内壁との接触面積を小さくできるため、腸内壁への付着を抑制できる。その結果、腸内壁への付着に伴う便秘を防ぐことが可能になる。 Also, since the spherical activated carbon has a large number of protrusions formed on the surface, the contact area with the intestinal inner wall can be reduced as compared with the spherical activated carbon having a smooth surface, so that adhesion to the intestinal inner wall can be suppressed. As a result, it becomes possible to prevent constipation associated with adhesion to the intestinal inner wall.
以下、本発明の実施例を詳細に説明する。 Hereinafter, embodiments of the present invention will be described in detail.
(実施例1)
温度計、撹拌装置および還流冷却器を備えた反応容器内にフェノール500質量部、8質量%の水分を含む固形状のパラホルムアルデヒド260質量部、水750質量部、ドデシルベンゼンスルホン酸5質量部およびアラビアゴム(セネガル種)0.2質量部を仕込んだ後、内容物を撹拌しながら加熱して反応させた。反応後、反応容器内を室温まで冷却し、濾過後に洗浄して硬化球状フェノール樹脂を得た。得られた硬化球状フェノール樹脂300質量部をロータリーキルンに仕込んだ後、650℃まで加熱して1時間焼成した。焼成にひきつづいて、水を投入しながら1000℃まで加熱し、0.5時間水蒸気賦活を行った後、室温まで冷却して球状活性炭を製造した。
Example 1
In a reaction vessel equipped with a thermometer, a stirrer and a reflux condenser, 500 parts by mass of phenol, 260 parts by mass of solid paraformaldehyde containing 8% by mass of water, 750 parts by mass of water, 5 parts by mass of dodecylbenzenesulfonic acid, and After charging 0.2 parts by mass of gum arabic (Senegal seed), the contents were heated and reacted with stirring. After the reaction, the inside of the reaction vessel was cooled to room temperature and washed after filtration to obtain a cured spherical phenol resin. 300 parts by mass of the obtained cured spherical phenol resin was charged into a rotary kiln, and then heated to 650 ° C. and baked for 1 hour. Subsequent to firing, the mixture was heated to 1000 ° C. while adding water, subjected to steam activation for 0.5 hours, and then cooled to room temperature to produce spherical activated carbon.
(実施例2)
実施例1と同様な方法で得た硬化球状フェノール樹脂300質量部をロータリーキルンに仕込んだ後、900℃まで加熱して1時間焼成した。焼成にひきつづいて、水を投入しながら1000℃まで加熱し、0.5時間水蒸気賦活を行った後、室温まで冷却して球状活性炭を製造した。
(Example 2)
300 parts by mass of the cured spherical phenol resin obtained by the same method as in Example 1 was charged into a rotary kiln, and then heated to 900 ° C. and baked for 1 hour. Subsequent to firing, the mixture was heated to 1000 ° C. while adding water, subjected to steam activation for 0.5 hours, and then cooled to room temperature to produce spherical activated carbon.
(実施例3)
実施例1と同様な方法で得た硬化球状フェノール樹脂300質量部をロータリーキルンに仕込んだ後、900℃まで加熱して1時間焼成した。焼成にひきつづいて、800℃まで冷却し、水を投入しながら3時間水蒸気賦活を行った後、室温まで冷却して球状活性炭を製造した。
(Example 3)
300 parts by mass of the cured spherical phenol resin obtained by the same method as in Example 1 was charged into a rotary kiln, and then heated to 900 ° C. and baked for 1 hour. Subsequent to the firing, the mixture was cooled to 800 ° C., subjected to steam activation for 3 hours while adding water, and then cooled to room temperature to produce spherical activated carbon.
(実施例4)
実施例1と同様な方法で得た硬化球状フェノール樹脂300質量部をロータリーキルンに仕込んだ後、900℃まで加熱して1時間焼成した。焼成にひきつづいて、800℃まで冷却し、水を投入しながら4時間水蒸気賦活を行った。再度、1000℃まで加熱して0.5時間焼成を行った後、室温まで冷却して球状活性炭を製造した。
Example 4
300 parts by mass of the cured spherical phenol resin obtained by the same method as in Example 1 was charged into a rotary kiln, and then heated to 900 ° C. and baked for 1 hour. Following the firing, the mixture was cooled to 800 ° C., and steam activation was carried out for 4 hours while adding water. After heating again to 1000 degreeC and baking for 0.5 hour, it cooled to room temperature and manufactured spherical activated carbon.
(実施例5)
実施例1と同様な方法で得た硬化球状フェノール樹脂300質量部をロータリーキルンに仕込んだ後、900℃まで加熱して1時間焼成した。焼成にひきつづいて、800℃まで冷却し、水を投入しながら5時間水蒸気賦活を行った後、室温まで冷却して球状活性炭を製造した。
(Example 5)
300 parts by mass of the cured spherical phenol resin obtained by the same method as in Example 1 was charged into a rotary kiln, and then heated to 900 ° C. and baked for 1 hour. Following the firing, the mixture was cooled to 800 ° C., and steam activation was performed for 5 hours while adding water, and then cooled to room temperature to produce spherical activated carbon.
(比較例1)
実施例1と同様な方法で得た硬化球状フェノール樹脂300質量部をロータリーキルンに仕込んだ後、900℃まで加熱して1時間焼成した。焼成にひきつづいて、800℃まで冷却し、水を投入しながら2時間水蒸気賦活を行った後、室温まで冷却して球状活性炭を製造した。
(Comparative Example 1)
300 parts by mass of the cured spherical phenol resin obtained by the same method as in Example 1 was charged into a rotary kiln, and then heated to 900 ° C. and baked for 1 hour. Subsequent to firing, the mixture was cooled to 800 ° C., subjected to steam activation for 2 hours while adding water, and then cooled to room temperature to produce spherical activated carbon.
得られた実施例1~5および比較例1の球状活性炭について、表面状態(突起の形態)、細孔容積、比表面積、平均粒子径および粒子硬度を下記方法により測定した。これらの結果を下記表1に示す。 For the obtained spherical activated carbons of Examples 1 to 5 and Comparative Example 1, the surface state (protrusion shape), pore volume, specific surface area, average particle diameter and particle hardness were measured by the following methods. These results are shown in Table 1 below.
1.表面状態(突起の形態)
球状活性炭表面の3箇所でSEM写真(倍率:25000倍)を撮影した。SEM写真は、球状活性炭を投影した面に相当する。図1~図6は、実施例1~5および比較例1の球状活性炭の代表的なSEM写真をそれぞれ示す。これらのSEM写真から実施例1~5および比較例1の球状活性炭は、外縁の少なくとも一部に曲線を持つ形状(例えば円、楕円、外縁の一部が直線である扁平楕円等)を有する多数の突起がその表面に混在して形成されていることを確認した。
1. Surface condition (protrusion shape)
SEM photographs (magnification: 25000 times) were taken at three locations on the surface of the spherical activated carbon. The SEM photograph corresponds to a surface on which spherical activated carbon is projected. 1 to 6 show representative SEM photographs of the spherical activated carbons of Examples 1 to 5 and Comparative Example 1, respectively. From these SEM photographs, the spherical activated carbons of Examples 1 to 5 and Comparative Example 1 have many shapes having a curve at least at a part of the outer edge (for example, a circle, an ellipse, a flat ellipse whose part of the outer edge is a straight line, etc.). It was confirmed that no protrusions were formed on the surface.
これらのSEM写真から球状活性炭表面に形成された外縁の少なくとも一部に曲線を持つ形状の突起を観察し、外縁の2点から中心を横切る長さのうちの最大長さを突起の径として測定した。下記表1には、実施例1~5および比較例1の球状活性炭表面に形成された多数の突起のうち、最小径および最大径を示す。 From these SEM photographs, observe the protrusion with a curved shape on at least a part of the outer edge formed on the surface of the spherical activated carbon, and measure the maximum length of the length across the center from two points on the outer edge as the diameter of the protrusion did. Table 1 below shows the minimum diameter and the maximum diameter among the many protrusions formed on the spherical activated carbon surfaces of Examples 1 to 5 and Comparative Example 1.
また、前記3つのSEM写真に映し出された突起の個数をそれぞれ計測した。計測した突起個数をSEM写真の倍率から求めた面積で除すことにより、各SEM写真に映し出された突起の1μm2当たりの個数を計算した。3つSEM写真から計算した1μm2当たりの突起の個数を加算し、この加算個数を3で除すことにより、球状活性炭表面の1μm2当たりの突起個数の平均値を求めた。その結果を下記表1に示す。なお、SEM写真の視野に存在する突起がその視野の縁部で欠けている場合には、欠けた突起が正規の大きさの半分以上である突起は1個として計測し、それ未満の突起は計測の対象から除外した。また、下記表1の1μm2当たりの突起個数は小数点1位を四捨五入した値である。 Further, the number of protrusions projected on the three SEM photographs was measured. By dividing the measured number of protrusions by the area obtained from the magnification of the SEM photograph, the number of protrusions projected on each SEM photograph per 1 μm 2 was calculated. The average number of protrusions per 1 μm 2 on the surface of the spherical activated carbon was determined by adding the number of protrusions per 1 μm 2 calculated from the three SEM photographs and dividing this added number by 3. The results are shown in Table 1 below. In addition, when a protrusion existing in the field of view of the SEM photograph is missing at the edge of the field of view, the number of protrusions in which the missing protrusion is half or more of the normal size is measured. Excluded from measurement. The number of protrusions per 1 μm 2 in Table 1 below is a value obtained by rounding off the first decimal place.
図7、図8は、それぞれ下記表1に示す細孔容積、比表面積、平均粒子径および粒子硬度を有する比較例2(市販品1)および比較例3(市販品2)の球状活性炭のSEM写真である。これらのSEM写真から比較例2,3の球状活性炭はいずれも表面が実質的に平滑であることを確認した。 7 and 8 are SEMs of spherical activated carbons of Comparative Example 2 (commercial product 1) and Comparative Example 3 (commercial product 2) having the pore volume, specific surface area, average particle diameter and particle hardness shown in Table 1 below, respectively. It is a photograph. From these SEM photographs, it was confirmed that the surfaces of the spherical activated carbons of Comparative Examples 2 and 3 were substantially smooth.
2.比表面積および細孔容積
球状活性炭を減圧下、300℃、3時間の前処理を行った後、比表面積・細孔分布測定装置(ユアサアイオニクス社製;NOVA4000e)を用いて窒素ガス吸着法により比表面積および細孔容積を測定した。
2. Specific surface area and pore volume After pre-treatment of spherical activated carbon under reduced pressure at 300 ° C. for 3 hours, a specific surface area / pore distribution measuring device (manufactured by Yuasa Ionics Co., Ltd .; NOVA4000e) was used for the nitrogen gas adsorption method. Specific surface area and pore volume were measured.
比表面積および細孔容積は、相対圧(P/P0)0.02~0.2における多点BET法にて測定を行なった。 The specific surface area and pore volume were measured by the multipoint BET method at a relative pressure (P / P 0 ) of 0.02 to 0.2.
また、直径1nm以下の細孔の容積率はMP法により細孔分布を測定し、直径1nm以下の細孔の総細孔容積の全細孔容積に占める割合を算出することにより求めた。 The volume ratio of pores having a diameter of 1 nm or less was determined by measuring the pore distribution by the MP method and calculating the ratio of the total pore volume of pores having a diameter of 1 nm or less to the total pore volume.
3.球状活性炭の平均粒子径
粒度分布測定装置(日機装社製;マイクロトラック粒度分布測定装置 9320HRA(x-100))を用いて球状活性炭の粒子径分布を光散乱法で測定した。この粒子径分布から粒子全体の体積を100%として累積曲線を求めたとき、その曲線が50%になる点の粒子径を平均粒子径として求めた。すなわち、累積平均径(中心径:Median径)を平均粒子径とした。
3. Average particle size of spherical activated carbon The particle size distribution of spherical activated carbon was measured by a light scattering method using a particle size distribution measuring device (manufactured by Nikkiso Co., Ltd .; Microtrac particle size distribution measuring device 9320HRA (x-100)). From this particle size distribution, when the cumulative curve was determined by setting the volume of the entire particle to 100%, the particle size at which the curve reached 50% was determined as the average particle size. That is, the cumulative average diameter (center diameter: Median diameter) was taken as the average particle diameter.
4.球状活性炭の粒子強度
球状活性炭から355μm以上、425μm未満の粒径に篩分けした。この粒子1個を加重し、粒子が潰れたときの荷重を測定し、次式から粒子強度を算出した。測定装置は、粒子硬度測定装置(岡田精工社製:グラノ)を用いた。
4). Particle strength of spherical activated carbon The spherical activated carbon was sieved to a particle size of 355 μm or more and less than 425 μm. One particle was weighted, the load when the particle was crushed was measured, and the particle strength was calculated from the following equation. As the measuring device, a particle hardness measuring device (Okada Seiko Co., Ltd .: Grano) was used.
粒子強度(G)=4P/πD2
ここで、Pは粒子が潰れたときの荷重(g)、
Dは粒子径(mm)、
である。
Particle strength (G) = 4P / πD 2
Where P is the load (g) when the particles are crushed,
D is the particle diameter (mm),
It is.
次いで、実施例1~5および比較例1~3の球状活性炭によるインドール(有害な毒性物質)およびトリプトファン、リジン(いずれも生体の必要物質)の吸着性能を以下の試験に従って測定した。その結果を下記表2に示す。 Next, the adsorption performance of indole (hazardous toxic substance), tryptophan, and lysine (both necessary substances for living body) by the spherical activated carbon of Examples 1 to 5 and Comparative Examples 1 to 3 was measured according to the following test. The results are shown in Table 2 below.
<インドール吸着試験>
各球状活性炭を105℃、2時間乾燥する前処理を施した後、正確に0.01g秤量し、共栓付き三角フラスコに入れた。pH7.4のリン酸塩緩衝液で調製した濃度50ppmのインドール原液を50mLホールピペットを用いて正確に採取し、前記三角フラスコに全量移した。つづいて、三角フラスコを40℃の水浴中に置き、3時間振盪した。振盪後、三角フラスコから液を採取し、孔径0.45μmのクロマトディスクで濾過した。濾過液について波長265nmの光の吸光度を測定し、吸着量を算出した。すなわち、インドール原液0%(pH7.4のリン酸塩緩衝液)、25%、50%、75%および100%での吸光度を測定してインドール濃度と吸光度の関係を示す検量線を作成した。実測した吸光度をこの検量線に照合して濾過液のインドール濃度を算出した。算出したインドール濃度で初期インドール濃度を差し引くことにより各球状活性炭のインドール吸着量を求めた。
<Indole adsorption test>
Each spherical activated carbon was pretreated by drying at 105 ° C. for 2 hours, and then accurately weighed 0.01 g and put into a conical flask with a stopper. An indole stock solution having a concentration of 50 ppm prepared with a phosphate buffer solution at pH 7.4 was accurately collected using a 50 mL whole pipette and transferred to the Erlenmeyer flask. Subsequently, the Erlenmeyer flask was placed in a 40 ° C. water bath and shaken for 3 hours. After shaking, the liquid was collected from the Erlenmeyer flask and filtered through a chromatodisc having a pore size of 0.45 μm. The absorbance of light with a wavelength of 265 nm was measured for the filtrate, and the amount of adsorption was calculated. That is, the absorbance at 0% indole stock solution (pH 7.4 phosphate buffer), 25%, 50%, 75% and 100% was measured to prepare a calibration curve showing the relationship between the indole concentration and the absorbance. The actually measured absorbance was collated with this calibration curve to calculate the indole concentration of the filtrate. The indole adsorption amount of each spherical activated carbon was determined by subtracting the initial indole concentration from the calculated indole concentration.
<トリプトファン吸着試験>
トリプトファン原液が100ppm、振盪時の温度が37℃、吸光度測定時の光波長が280nmである以外、インドール吸着試験に準じて各球状活性炭のトリプトファン吸着量を求めた。
<Tryptophan adsorption test>
The tryptophan adsorption amount of each spherical activated carbon was determined according to the indole adsorption test except that the tryptophan stock solution was 100 ppm, the temperature at shaking was 37 ° C., and the light wavelength at the time of absorbance measurement was 280 nm.
<リジン吸着試験>
各球状活性炭を105℃、2時間乾燥する前処理を施した後、正確に0.01g秤量し、共栓付き三角フラスコに入れた。pH7.4のリン酸塩緩衝液で希釈した濃度100ppmのリジン原液を50mLホールピペットを用いて正確に採取し、前記三角フラスコに全量移した。つづいて、三角フラスコを37℃の水浴中に置き、3時間振盪した。振盪後、三角フラスコから液を採取し、孔径0.45μmのクロマトディスクで濾過した。濾過液についてアミノ酸分析器(日本電子社;JLC-500/V2)および高分解カラムを用いてアミノ酸分析を行なった。この分析で測定されたリジン濃度で初期リジン濃度を差し引くことにより各球状活性炭のリジン吸着量を求めた。
Each spherical activated carbon was pretreated by drying at 105 ° C. for 2 hours, and then accurately weighed 0.01 g and put into a conical flask with a stopper. A lysine stock solution having a concentration of 100 ppm diluted with a phosphate buffer solution at pH 7.4 was accurately collected using a 50 mL whole pipette, and transferred to the Erlenmeyer flask. Subsequently, the Erlenmeyer flask was placed in a 37 ° C. water bath and shaken for 3 hours. After shaking, the liquid was collected from the Erlenmeyer flask and filtered through a chromatodisc having a pore size of 0.45 μm. The filtrate was subjected to amino acid analysis using an amino acid analyzer (JEOL Ltd .; JLC-500 / V2) and a high resolution column. The amount of lysine adsorbed on each spherical activated carbon was determined by subtracting the initial lysine concentration from the lysine concentration measured in this analysis.
前記表1、表2から明らかなように実施例1~5の球状活性炭は、表面に突起がなく平滑で、かつ直径1nm以下の細孔の容積率が本発明の上限値45%を超える市販品である比較例2,3の球状活性炭に比べてインドールの吸着性が僅かに劣るものがあるものの、生体の必要物質であるトリプトファンおよびリジンの吸着性が低く、インドールの選択吸着性に優れていることがわかる。 As apparent from Tables 1 and 2, the spherical activated carbons of Examples 1 to 5 are commercially available with no protrusions on the surface and smooth, and the volume ratio of pores having a diameter of 1 nm or less exceeds the upper limit of 45% of the present invention. Although the indole adsorptivity is slightly inferior to the spherical activated carbons of Comparative Examples 2 and 3, which are products, the adsorbability of tryptophan and lysine, which are vital substances, is low, and the indole selective adsorptivity is excellent. I understand that.
また、比較例1の球状活性炭は表面に多数の突起が形成されているものの、直径1nm以下の細孔の容積率が本発明の下限値30%未満(29.6%)であるため、インドールの吸着性が実施例1~5の球状活性炭に比べて極端に低くなることがわかる。 In addition, although the spherical activated carbon of Comparative Example 1 has a large number of protrusions on the surface, the volume ratio of pores having a diameter of 1 nm or less is less than 30% (29.6%) of the lower limit of the present invention. It can be seen that the adsorptivity of is extremely lower than the spherical activated carbons of Examples 1 to 5.
以上、本発明によればインドールのような有害な毒性物質の吸着性が高く、トリプトファン、リジンのような生体の必要物質の吸着性が低い、有害な毒性物質の選択吸着性に優れ、腎臓機能が低下した患者の治療薬として有用な経口投与用吸着剤を提供することができる。 As described above, according to the present invention, the adsorptivity of harmful toxic substances such as indole is high, the adsorptivity of necessary substances such as tryptophan and lysine is low, the selective adsorptivity of harmful toxic substances is excellent, and the kidney function Therefore, it is possible to provide an adsorbent for oral administration that is useful as a therapeutic agent for patients with reduced blood pressure.
Claims (8)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008544700A JP4268672B1 (en) | 2008-07-04 | 2008-07-04 | Adsorbent for oral administration |
| PCT/JP2008/062219 WO2010001485A1 (en) | 2008-07-04 | 2008-07-04 | Adsorbent for oral administration |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP2008/062219 WO2010001485A1 (en) | 2008-07-04 | 2008-07-04 | Adsorbent for oral administration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2010001485A1 true WO2010001485A1 (en) | 2010-01-07 |
Family
ID=40785256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2008/062219 Ceased WO2010001485A1 (en) | 2008-07-04 | 2008-07-04 | Adsorbent for oral administration |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP4268672B1 (en) |
| WO (1) | WO2010001485A1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014129615A1 (en) * | 2013-02-22 | 2014-08-28 | 株式会社クレハ | Orally administered adsorbent, therapeutic agent for renal disease, and therapeutic agent for liver disease |
| WO2014129614A1 (en) * | 2013-02-22 | 2014-08-28 | 株式会社クレハ | Orally administered adsorbent, therapeutic agent for renal disease, and therapeutic agent for liver disease |
| JP2017507126A (en) * | 2014-02-07 | 2017-03-16 | テウォン ファーム カンパニー リミテッド | Orally administered pharmaceutical adsorbent with increased strength |
| US9877987B2 (en) | 2013-02-22 | 2018-01-30 | Kureha Corporation | Orally administered adsorbent, therapeutic agent for renal disease, and therapeutic agent for liver disease |
| CN115253762A (en) * | 2022-08-27 | 2022-11-01 | 西畔(北京)信息技术有限责任公司 | Active carbon oral pill, preparation device and preparation method |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004039381A1 (en) * | 2002-11-01 | 2004-05-13 | Kureha Chemical Industry Co., Ltd. | Adsorbents for oral administration, remedies or preventives for kidney diseases and remedies or preventives for liver diseases |
| JP2004244414A (en) * | 2003-01-22 | 2004-09-02 | Meruku Hoei Kk | Pharmaceutical adsorbent and its production method |
| JP2006008602A (en) * | 2004-06-25 | 2006-01-12 | Ajinomoto Co Inc | Peroral uremic toxin adsorbent |
| JP2006131461A (en) * | 2004-11-08 | 2006-05-25 | Japan Organo Co Ltd | Activated carbon, its manufacturing method, and renal disease therapeutic drug |
| JP2006256882A (en) * | 2005-03-15 | 2006-09-28 | Japan Organo Co Ltd | Activated carbon, its production method, and therapeutic agent for kidney/liver disorders |
| JP2007045775A (en) * | 2005-08-11 | 2007-02-22 | Japan Organo Co Ltd | Hydrous activated carbon and method for producing the same |
| JP2007197338A (en) * | 2006-01-24 | 2007-08-09 | Merck Seiyaku Kk | Pharmaceutical adsorbent |
-
2008
- 2008-07-04 WO PCT/JP2008/062219 patent/WO2010001485A1/en not_active Ceased
- 2008-07-04 JP JP2008544700A patent/JP4268672B1/en not_active Expired - Fee Related
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004039381A1 (en) * | 2002-11-01 | 2004-05-13 | Kureha Chemical Industry Co., Ltd. | Adsorbents for oral administration, remedies or preventives for kidney diseases and remedies or preventives for liver diseases |
| JP2004244414A (en) * | 2003-01-22 | 2004-09-02 | Meruku Hoei Kk | Pharmaceutical adsorbent and its production method |
| JP2006008602A (en) * | 2004-06-25 | 2006-01-12 | Ajinomoto Co Inc | Peroral uremic toxin adsorbent |
| JP2006131461A (en) * | 2004-11-08 | 2006-05-25 | Japan Organo Co Ltd | Activated carbon, its manufacturing method, and renal disease therapeutic drug |
| JP2006256882A (en) * | 2005-03-15 | 2006-09-28 | Japan Organo Co Ltd | Activated carbon, its production method, and therapeutic agent for kidney/liver disorders |
| JP2007045775A (en) * | 2005-08-11 | 2007-02-22 | Japan Organo Co Ltd | Hydrous activated carbon and method for producing the same |
| JP2007197338A (en) * | 2006-01-24 | 2007-08-09 | Merck Seiyaku Kk | Pharmaceutical adsorbent |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014129615A1 (en) * | 2013-02-22 | 2014-08-28 | 株式会社クレハ | Orally administered adsorbent, therapeutic agent for renal disease, and therapeutic agent for liver disease |
| WO2014129614A1 (en) * | 2013-02-22 | 2014-08-28 | 株式会社クレハ | Orally administered adsorbent, therapeutic agent for renal disease, and therapeutic agent for liver disease |
| JPWO2014129614A1 (en) * | 2013-02-22 | 2017-02-02 | 株式会社クレハ | Adsorbent for oral administration, therapeutic agent for kidney disease and therapeutic agent for liver disease |
| JPWO2014129615A1 (en) * | 2013-02-22 | 2017-02-02 | 株式会社クレハ | Adsorbent for oral administration, therapeutic agent for kidney disease and therapeutic agent for liver disease |
| US9877987B2 (en) | 2013-02-22 | 2018-01-30 | Kureha Corporation | Orally administered adsorbent, therapeutic agent for renal disease, and therapeutic agent for liver disease |
| JP2017507126A (en) * | 2014-02-07 | 2017-03-16 | テウォン ファーム カンパニー リミテッド | Orally administered pharmaceutical adsorbent with increased strength |
| CN115253762A (en) * | 2022-08-27 | 2022-11-01 | 西畔(北京)信息技术有限责任公司 | Active carbon oral pill, preparation device and preparation method |
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2010001485A1 (en) | 2011-12-15 |
| JP4268672B1 (en) | 2009-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI319985B (en) | Adsorbent for oral administration, agent for treating or preventing renal disease, and agent for treating or preventing liver disease | |
| JP3585043B2 (en) | Pharmaceutical adsorbent and its production method | |
| AU2012319495B2 (en) | Orally administered adsorbent | |
| JP5984352B2 (en) | Method for producing pharmaceutical adsorbent for oral administration | |
| JP4268672B1 (en) | Adsorbent for oral administration | |
| JP5124094B2 (en) | Pharmaceutical adsorbent | |
| JP5424177B2 (en) | Adsorbent for oral administration | |
| JP7631577B2 (en) | Oral tablet-type adsorbent | |
| TWI341732B (en) | Adsorbent for oral administration,agent for treating or preventing renal disease, and | |
| TWI532508B (en) | Adsorbent for oral administration, and agent for treating renal or liver disease | |
| TWI520751B (en) | Adsorbent for oral administration, and agent for treating renal or liver disease | |
| CN106029218B (en) | Oral pharmaceutical adsorbents with increased strength | |
| US20170252370A1 (en) | Adsorbent for oral administration, agent for treating renal disease, and agent for treating liver disease | |
| JP4875840B2 (en) | Activated carbon preparation for oral administration | |
| CN113874320B (en) | Method for manufacturing activated carbon adsorbent | |
| JP2016014057A (en) | Production method for sorbent for oral administration medicines | |
| JP4311923B2 (en) | Treatment or prevention agent for liver disease for oral administration | |
| JP7610765B1 (en) | Activated carbon adsorbent | |
| WO2021134482A1 (en) | Direct compressed activated carbon tablet formulation | |
| JP2021161100A (en) | Tablet-type adsorbent for oral administration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: 2008544700 Country of ref document: JP |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08790899 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 08790899 Country of ref document: EP Kind code of ref document: A1 |